Why This PepGen Analyst Is Bullish On The Biotech Stock
HC Wainwright initiated coverage of PepGen Inc (NASDAQ:PEPG) with a Buy rating and $26 price target. PepGen is developing next-generation antisense…
Benzinga’s Top Ratings Upgrades, Downgrades For December 21, 2022
Upgrades For PagSeguro Digital Ltd (NYSE:PAGS), New Street Research upgraded the previous rating of Neutral to Buy. In…
HC Wainwright & Co. Initiates Coverage On PepGen with Buy Rating, Announces Price Target of $26
HC Wainwright & Co. analyst Andrew Fein initiates coverage on PepGen (NASDAQ:PEPG) with a Buy rating and announces Price Target of $26.
Hillenbrand, Cisco, Macy’s And Other Big Gainers From Thursday
U.S. stocks closed slightly lower on Thursday, with the S&P 500 dropping around 0.3%. Here is the list of some big stocks recording gains in the previous session.
Why Tupperware Brands Shares Dipped Around 42%; Here Are 89 Biggest Movers From Yesterday
Gainers
Starry Group Holdings, Inc. (NYSE: STRY) rose 55.6% to close at $0.28 on Wednesday after reporting Q3 results.
Why Laser Photonics Shares Jumped By Around 44%; Here Are 72 Biggest Movers From Yesterday
Gainers
FedNat Holding Company (NASDAQ: FNHC) shares climbed 107.7% to close at $0.3395 on Tuesday.
Why Senti Biosciences Shares Jumped Over 50%; Here Are 79 Biggest Movers From Yesterday
Gainers
Senti Biosciences, Inc. (NASDAQ: SNTI) shares climbed 50.7% to close at $2.11 on Thursday after B of A Securities initiated coverage on the stock with a Buy rating and $7 price target.
Why Twin Vee Powercats Is Trading Lower By Over 30%; Here Are 30 Stocks Moving Premarket
Gainers
Windtree Therapeutics, Inc (NASDAQ: WINT) rose 50.7% to $0.4827 in pre-market trading after the company said Istaroxime Phase 2 study in early cardiogenic shock was published in the European Journal of Heart Failure.
Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday
Gainers
PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial met its primary endpoint.
